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Magnesium carbonate as a phosphorus binder: A prospective, con-
trolled, crossover study. The use of calcium carbonate (CaCO3) to bind
phosphorus (P) in chronic hemodialysis patients has been a popular tactic
in the past decade. Nonetheless, problems with hypercalcemia decrease its
usefulness, particularly in patients treated with calcitriol. A P binder not
containing calcium (Ca) would be of value in these circumstances. In
short-term studies, we showed that magnesium carbonate (MgCO5) was
well-tolerated and controlled P and Mg levels when given in conjunction
with a dialysate Mg of 0.6 mg/dl. We, therefore, performed a prospective,
randomized, crossover study to evaluate if the chronic use of MgCO3
would allow a reduction in the dose of CaCO3 and yet achieve acceptable
levels of Ca, P, and Mg. We also assessed whether the lower dose of
CaCO3 would facilitate the use of larger doses of calcitriol. The two phases
were MgCO3 plus half the usual dose of CaCO3 and CaCO3 alone given
in the usual dose. It was found that MgCO3 (dose, 465 52 mg/day
elemental Mg) allowed a decrease in the amount of elemental Ca ingested
from 2.9 0.4 to 1.2 0.2 glday (P < 0.0001). The Ca, P, Mg levels were
the same in the two phases. The maximum dose of iv. calcitriol without
causing hypercalcemia was 1.5 0.3 jgItreatment during the MgCO3
phase and 0.8 0.3 g/treatment during the Ca phase (P < 0.02). If these
studies are confirmed, the use of MgCO3 and a dialysate Mg of 0.6 mg/dl
may be considered in selected patients who develop hypercalcemia during
treatment with iv. calcitriol and CaCO3.
In chronic renal failure, control of serum phosphorus (P)
concentrations is a decisive factor in the prevention and treatment
of secondary hyperparathyroidism [1 1. Dietary P restriction may
be useful, but excessive limitations may lead to an inadequate
dietary protein intake and malnourishment. There are currently
no routine dialytic treatments or regimens that remove enough P
to maintain balance in the well-nourished patient [2, 3]. There-
fore, compounds that bind P in the bowel have been used with
some success for over 25 years. The initial enthusiasm for P
binders containing aluminum slowly faded when it was realized
that the metal accumulated systemically causing osteomalacia,
dementia, myopathy, and anemia [4—6]. Although Clarkson,
McDonald and de Wardener studied the effects of CaCO3 on P
absorption in 1966, its widespread popularity as a P binder has
been largely confined to the last decade [7]. Often large doses are
required and hypercalcemia is common, especially in those pa-
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tients with very high or low bone turnover 8, 9]. We have
previously found that decreasing the calcium (Ca) concentration
in the dialysate from 6.5 to 5 mg/dl allowed for excellent control
of P with CaCO3 without hypercalcemia [10]. Nonetheless, signif-
icant problems with phosphorus binders persist, particularly in
patients receiving calcitriol. Treatment with this sterol increases
both Ca and P absorption by the intestine [11]. Hence, patients
treated with calcitriol are at risk to develop hypercalcemia and
hyperphosphatemia. Acute studies have shown that P is bound by
half the amount of elemental Ca when given as calcium acetate
compared to carbonate [12, 13]. However, no long-term studies
have demonstrated that this results in less hypercalcemia [14—16].
A potent calcium-free P binder would be ideal. The P binding
properties of Mg were extensively studied by Fine et al in acute
studies involving normal subjects [17]. They found a dose-depen-
dent decrease in P absorption from 75% with placebo to 28% with
77 mEq magnesium acetate. The use of a P binder containing
magnesium (Mg) used in conjunction with a low or Mg-free
dialysate may therefore be a possible strategy in chronic renal
failure. In short-term studies, we have shown that a Mg-free
dialysate was poorly tolerated in patients undergoing high-effi-
ciency hemodialysis with one half developing severe muscle
cramps [18]. A dialysate containing 0.6 mg/dl, however, was well
tolerated when used in conjunction with magnesium carbonate
(MgCO3) to bind P. The purposes of the current study were: (1)
to determine if the chronic use of MgCO3 in conjunction with a
0.6 mg/dl Mg dialysate would allow a reduction in the dose of
CaCO3 and yet achieve acceptable levels of Ca, P and Mg; and (2)
to assess if the lower intake of CaCO3 would result in less




The criteria for selection of subjects included treatment of renal
failure with hemodialysis at our institution for more than six
months, parathyroid hormone (PTH) levels > 8.0 ng/ml, and good
dietary and medical compliance as assessed by the dietary,
nursing, and medical staff. No patient was treated with calcitriol
within the month preceding the start of the protocol. Twenty-nine
patients agreed to participate in the study. Six subjects died during
the two year study. The causes of death were an acute myocardial
infarction in four and sepsis in two subjects. Three were found to
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be non-compliant when the CaCO3 tablets were counted (see
below) during the run-in phase. Two subjects withdrew during the
run-in phase because of headaches and myalgias, respectively. A
severe intercurrent illness requiring a prolonged hospitalization
forced a withdrawal from the study in two subjects. One subject
transferred to a different dialysis unit. There was no relationship
between any of the study phases and patient withdrawal or death.
Thus, 15 subjects successfully completed the protocol. The age
was 58 four years (range 27 to 77). Six were male and nine
female. Twelve were black and three were white. The duration of
dialysis was 75 11 months (range 21 to 175). The causes of renal
failure were hypertension (7), diabetes (3), chronic glomerulone-
phritis (2), polycystic kidney disease (1), obstruction (1), and
systemic lupus erythematosus (1). No subject had a parathyroid-
ectomy. Written consent was obtained from all patients, and the
studies were approved by the Human Research Committee of
Washington University.
The Kt/V was maintained between 1.2 to 1.4 in all subjects with
reprocessed Clirans 175 (Terumo, Tokyo, Japan) dialyzers. The
blood flow was 450 mI/mm and dialysate flow 500 to 800 ml/min
with Fresenius 2008 D (Seratronics, Concord, CA, USA) dialysis
machines using bicarbonate dialysate.
Protocol
At the start of the run-in phase, subjects were switched from
generic CaCO1 to a single CaCO3 formulation (Calci-MIxTM 1250
mg, R&D Laboratories, Inc., Marina del Rey, CA, USA) to insure
uniform dissolution of the salt in binding dietary P in the subjects.
Calcium, P, Mg, and PTH levels were measured weekly in this
four- to eight-week period. The amounts of CaCO3 prescribed
were adjusted weekly to attain target serum Ca levels between 9.5
and 10.5 mg!dl and P levels less than 6 mg/dl. If the target levels
were attained for four consecutive weeks, subjects were random-
ized to a phase where they each received half the amount of
CaCO3 required in the run-in phase plus MgCO3 (Mg phase) or
a phase in which the amount of CaCO3 prescribed did not change
(Ca phase). The initial dose of MgCO3 was 750 mg/day (214 mg
elemental Mg), which was titrated weekly as necessary for four to
eight weeks to attain the target P of less than 6 mg/dl. If the target
Ca and P levels were achieved for four consecutive weeks, the
patients in both groups entered the calcitriol phase where 2 j.ig
was injected intravenously after each dialysis three times a week.
Calcium, P, Mg and PTH levels were measured weekly. If
hypercalcemia (Ca > 11 mg/dl) did not occur in this two week
period, the dose of calcitriol was increased to 3 ig after each
dialysis for two weeks. If the calcium levels remained  11 mgldl,
the dose was increased to its maximum of 4 jg i.v. three times a
week. This dose was continued for 10 weeks if hypercalcemia did
not occur. If hypercalcemia developed at any time, the calcitriol
was held and restarted at a dose of 3 ag when the hypercalcemia
resolved. If hypercalcemia recurred in the following 10 weeks, the
calcitriol was held and restarted when the serum Ca decreased to
< 11 mg/dl at a dose of 2 gig. The process was repeated using
doses of I jig, 0.5 tg, and 0 j.ig if Ca> 11 mg/dl was noted in the
weekly measurements. Thus, the outcome was the highest calcit-
rio! dose that did not cause hypercalcemia over a period of 10
weeks.
Upon successful completion of the 10 week period, calcitriol
was discontinued and all patients returned to the regimen used in
the run-in phase when the subjects were treated with CaCO5
alone. After four weeks of this washout phase, subjects entered
the other phase and were managed in a fashion identical to that
described above. Thus, the protocol was a randomized, prospec-
tive crossover design.
In both groups, the dialysate Ca was 5 mg/dl. When subjects
were treated with MgCO3, a dialysate Mg of 0.6 mg/dl was used.
This dialysate solution was prepared by mixing one volume of 1.8
mg/dl Mg dialysate (Naturalyte 9018, National Medical Care,
Rockleigh, NJ, USA) with two volumes of 0 mg/dl Mg dialysate
(Naturalyte 9032). During treatment with CaCO3 alone, the
dialysate Mg was 1.8 mg/dl. All subjects received erythropoietin
and oral iron.
During the entire protocol, the laboratory data were reviewed
weekly by the dietitians and nephrologists. Adjustments in the
binder regimen were made as necessary to attain the target Ca
and P levels. All binders were given with meals in proportion to
the estimated average P intake with each meal. Pill counts were
done weekly to ensure compliance. Three day diet histories, done
during the baseline phase, showed a dietary intake of 951 48,
438 46, and 180 12 mg/day for P, Ca, and Mg, respectively
[19]. The diet histories were repeated in the two phases and did
not change (data not shown). Alkaline phosphatase, albumin, and
potassium levels were measured monthly.
Measurements
The concentration of total Ca and Mg was determined by
atomic absorption spectroscopy (Model 503; Perkin-Elmer, Nor-
walk, CT, USA). The normal range of plasma Mg in our labora-
tory is 1.6 to 2.6 mg/dl. Phosphorus was measured by the
Technicon Autoanalyzer (Technicon Instruments, Tarrytown,
NY, USA). Serum levels of PTH were assessed by the CH9
antibody that recognizes the intact, midregion, and C-terminal
portion of the hormone. The normal range is 360 pg/ml. The
method has previously been described in detail [20].
Statistics
The Wilcoxon signed rank test was used to evaluate paired
nonparametric data. The t-test was applied to parametric data.
Spearman rank was used to test correlations. For statistical
analysis of three or more groups, a one-way repeated measures
analysis of variance was used for parametric data and Friedman
repeated measures analysis of variance on ranks for nonparamet-
nc data. The statistical software was SigmaStat (Jandel Scientific,
San Rafael, CA, USA). Results are reported as mean SEM.
Results
The mean of 10 weekly Ca, P, and Mg levels were calculated for
each subject in the Mg and Ca phases. There were no significant
differences (Fig. 1). The mean total Ca was 10.2 0.2 mg/dl
during the both the Mg and Ca phases. Both values were
statistically greater (P < 0.05) than the mean 10 weekly Ca levels
of 9.7 0.2 mg/dl measured during the run-in control phase. The
mean P level was 5.7 0.2 mg/dl during the Mg phase and 5.2
0.2 mg/dl in the Ca phase. These values were not different but
were marginally higher than the levels of 4.9 0.2 mg/dl in the
run-in phase (P = 0.06). The Mg levels were 2.9 0.2 and 3 0.1
mgldl in the Mg and Ca phases, respectively. These were not
different from the run-in phase where the mean Mg levels were 3.1
0.1 mg/dl. The control of P in the Mg phase occurred despite
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Fig. 1. Mean SE of 10 weekly Ca, P, and Mg calculated from each subject(N = 15) in the two phases. Symbols are: () MgCO3; () CaCO3.
Fig. 2. Mean SE dose of elemental Ca and Mg used to bind P in the two
phases. Symbols are: ) MgCO3; () CaCO3.
the Ca phase. As shown in Figure 2, the amount of elemental Ca
used was 1.2 0.2 glday during the Mg phase and 2.9 0.4 g!day
during the Ca phase (P < 0.0001). The elemental Ca ingested
during the run-in phase was 3.0 0.4 g/day, a value not different
from the CaCO3 phase. The mean dose of elemental Mg pre-
scribed to bind phosphorus in the Mg phase was 465 52 mg/day
(range 214 to 858 mg/day). Despite the relatively large dose of
MgCO3, the binder was well tolerated. No subject developed
gastrointestinal symptoms such as loose stools, diarrhea, or bloat-
ing. As previously reported, the dialysate Mg concentration of 0.6
mg/dl was also well accepted with no adverse clinical sequelae
[181.
The total number of episodes of hypercalcemia per patient
while receiving any dose of calcitriol was 1.8 0.2 during the Mg
phase and 2.7 0.3 during the Ca phase (P = 0.03). The overall
incidence of hypercalcemia was 8.9% with mean hypercalcemic
values of 11.6 0.2 mg/dl (range 11.1 to 14.4 mg/dl). One patient
developed pruritus and nausea which lasted two days after the
discontinuation of calcitriol.
The lower dose of CaCO3 allowed for the administration of a
higher dose of calcitriol without causing hypercalcemia. As shown
Fig. 3. Maximum tolerated dose of i. v. calcitriol in the two phases. See text
for the definition of maximal tolerated dose of intravenous calcitriol. P <
0.02.
in Figure 3, the mean tolerated calcitriol dose was 1.5 0.3
xg/treatment during the Mg phase and 0.8 0.3 rg/treatment
during the Ca phase (P < 0.02). There were no differences in the
mean PTH levels in the Mg and Ca phases (47 8 ng/ml vs. 48
10 ng/ml, respectively). If, however, the percent difference in PTH
levels in the Ca phase versus Mg phase was plotted against the
absolute difference in calcitriol dose (xg, Mg phase — Ca phase),
a highly significant reciprocal relationship was found (r =
—0.8468, P < 0.0001). The albumin levels were 3.9 0.1, 3.9
0.1, and 4.0 0.1 g/dl in the Mg, Ca, and run-in phase,
respectively. The alkaline phosphatase level in the run-in phase
was 92 8 lU/liter. This value, although within the normal range
(38 to 126 lU/liter), was greater than those of the Mg and Ca
phases, where they were 78 6 and 78 9 lU/liter, respectively
(P < 0.05). The mean potassium levels were 4.9 0.1 in the Mg
phase and 4.9 0.1 mEq/liter in the Ca phase (P = NS).
Discussion
Several investigators have evaluated the use of Mg-containing P
binders in dialysis patients. Guillot et a! treated nine patients
undergoing conventional hemodialysis with Mg(OH)2 for three to
five weeks [211. Using doses averaging 734 mg of elemental
Mg/day and dialysate Mg concentrations of 1.2 to 1.8 mg/dl, the P
levels fell from a control (no binders) value of 9.0 to 8.1 mg'dl.
The mean Mg levels were 4.32 mg/dl. Four of nine developed
diarrhea. Mactier et al could find no effect of Mg Trilisate on P
levels in either hemodialysis or peritoneal dialysis patients [22].
Eighteen patients undergoing conventional hemodialysis were
switched from Al(OH)3 to Mg(OH)2 by Oe et al [23]. The P levels
rose from 4.3 to 6.1 mg/dl despite an average intake of 991 mg of
elemental Mg. The Mg level averaged 4.3 mg/dl while the patients
received Mg(OH)2 and were treated with a dialysate devoid of
Mg. The potassium levels were significantly higher when patients
received Mg(OH)2 compared to the control phase (5.7 0.3 vs.
5.1 0.4 mEq/liter). More favorable results were reported by
O'Donovan et al [24]. They switched 28 patients undergoing
conventional hemodialysis from A!(OH)3 to MgCO3 in combina-
tion with a Mg-free dialysate. Over the two-year study period, Ca,
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in the control phase. The amount of elemental Mg used varied
between 155 to 465 mg/day, doses similar to this study. Diarrhea
was mild and transient. Similar data were reported by Moriniere
et at [25]. They also reported severe hyperkalemia as high as 8
mEq/liter in many patients, the etiology of which was unclear.
More recently, this same group performed a controlled study
where patients were either treated with CaCO3 plus Mg(OH)2 as
needed or Mg(OH)2 alone and 1-alpha-hydroxyvitamin D3 [26].
The latter group was not superior to the former in suppressing
PTH secretion due to uncontrolled hyperphosphatemia causing a
reduction in the dose of 1-alpha-vitamin D3.
It is noteworthy that P levels did not increase despite decreasing
the dose of elemental Ca by art average of 85 mEq/day while
prescribing an average of 39 mEq/day of Mg. This would imply
that MgCO3 is a more potent P binder than CaCO3. In vitro
studies, however, suggest that Mg, when studied in the form of
Mg(OH)2, is less effective that CaCO3 [13]. Acute studies in
normal subjects also suggest that CaCO3 is a more effective P
binder than magnesium acetate [13, 17]. There are a number of
possible explanations for this apparent discrepancy. The P binding
properties of Mg and Ca salts may change when given chronically.
It is also conceivable that Mg and Ca salts may act synergistically
to bind P, although this has not been studied. Finally, there may
be differences in P binding between the different salts of Mg. To
our knowledge, there has been no direct comparison of the
efficacy or tolerance of various Mg salts in the setting of renal
failure. Finally, the similar P levels in the two groups may not
represent comparable gastrointestinal absorption of P. Magne-
sium and other salts can also affect P levels by altering skeletal and
soft tissue deposition and/or resorption.
In the current study, we reasoned that MgCO3 would he a
useful adjunct to CaCO3 in binding P and that lowering the
amount of CaCO3 ingested would allow for the administration of
higher doses of calcitriol, This was found to be correct. The
dialysate Mg concentration of 0.6 mg/dl was well tolerated and did
not cause the muscle cramps we previously observed with patients
undergoing high efficiency hemodialysis using a dialysate devoid
of Mg. In addition, the use of MgCO3 as a P binder was well
tolerated with no gastrointestinal side effects. This is in contrast to
the studies previously cited. Possible reasons for the tolerance
include the use of CO3 instead of OH2 as the anion, the
concomitant administration of CaCO3 and/or ferrous sulfate, and
the use of smaller amounts of elemental Mg to bind P. We found
no differences in the Ca levels in the two phases despite admin-
istering twice the amount of calcitriol in the Mg phase. Presum-
ably this was due to the lower dose of CaCO3 used for P binding.
That the P levels were similar in the two phases attests to the
efficacy of using MgCO3 as a phosphorus binder. The similar
values of Mg in the two phases reflected, in part, the greater
removal of Mg with the dialysate lower in Mg. We have previously
reported a net removal of 306 69 mg/treatment using a dialysate
Mg of 0.6 mg/dl versus 56 50 mg/treatment with a concentration
of 1.8 mg/dl. The net Mg balances in the two phases, however, was
beyond the scope of the study.
Most investigators have shown a good correlation between
bone and serum Mg. It is not surprising that bone Mg is elevated
in renal failure. The consequences of this are controversial. It has
been suggested that Mg may inhibit the formation of appatite
ciystals and thereby inhibit bone formation in vitro [27, 28]. In
support of this contention is the finding by Gonella et at that bone
mineralization improved in six patients after the dialysate Mg was
decreased to 0.6 mg/dl [29]. However, Moririiere, Vinatier and
Westeel noted no significant changes in bone histomorphology
after 8 to 20 months of treatment with Mg(OH)2, during which
time the Mg levels averaged 3.6 mg/dl [25]. Mg may have
beneficial vascular effects. Meema, Oreopoulos and Rapaport, for
example, found that patients on peritoneal dialysis with high levels
of serum Mg had less evidence of vascular calcification than those
with lower levels [30]. They postulated that Mg may inhibit the
calcification process.
Although the PTH levels were lower in both the Mg and Ca
phases than the control run-in phase, they were not different
between the two experimental phases. A likely reason is that PTH
levels were not a primary end-point in our study design. None-
theless, the suppression of PTH was dose-dependent. This seem-
ingly inconsistency was due to the lower levels of PTH in the Ca
phase seen in those patients whose calcitriol dose was the same in
both phases. Cantley et al have clearly shown that calcitriol
suppresses PTH secretion in a dose-dependent manner in vitro
[31]. Nonetheless, patients in the Mg phase tolerated a higher
dose of calcitriol without the development of hypercalcemia
compared to the Ca phase.
Although we found the strategy of using MgCO3 to bind P in
conjunction with a low Mg dialysate and decreased dose of CaCO3
to be well tolerated and efficacious in this study, further investi-
gations are warranted before it can be recommended. These
would need to include an evaluation of bone histomorphology.
Nonetheless, its use may be considered in selected hemodialysis
patients with severe hyperparathyroidism whose treatment with
calcitriol is limited by the development of hypercalcemia and/or
hyperphosphatemia.
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